LENAVA
Description
Lenalidomideis an immunomodulatory drug and also thalidomide analogue, It was initially intended as a treatment for multiple myeloma, for which thalidomide is an accepted therapeutic treatment. Lenalidomide has also shown efficacy in the class of hematological disorders known as myelodysplastic syndromes (MDS). Along with several other drugs developed in recent years, It has significantly improved overall survival in myeloma. It cannotbe prescribed for women who are pregnant or who might be conceiving.
Indications:
- For the treatment of Multiple myeloma (MM), in combination with dexamethasone.
- Transfusion dependent anemia due to low or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities.
- Mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib.
| Generic Name | Strength | Standard | Type | Packing | Pack Size |
| Lenalidomide | 2.5 /5 / 10/15/25 mg | IP/USP | Capsule | Bottle | 1 X 10 |